Assignee
SCANCELL LTD
GB·9 granted patents·9 pending applications·15 citations·filing 1999–2022
Top patents by PatentIndex Score
18 records- 0185US10233220B2Anti-tumour response to modified self-epitopesSCANCELL LTD·Filed 2015·Granted Mar 19, 2019·4 cites·10 claims
- 0283US7267821B2Binding member which binds to both Lewisy and Lewisb haptens, and its use for treating cancerSCANCELL LTD·Filed 2002·Granted Sep 11, 2007·9 cites·7 claims
- 0376US12258377B2Anti-tumour response to modified self-epitopesSCANCELL LTD·Filed 2022·Granted Mar 25, 2025·0 cites·12 claims
- 0467US2021198334A1Anti-Tumour Response to Modified Self-EpitopesSCANCELL LTD·Filed 2020·Application pending·0 cites
- 0566US10695438B2Anti-tumour immune responses to modified self-epitopesSCANCELL LTD·Filed 2016·Granted Jun 30, 2020·1 cites·14 claims
- 0662US2018346537A1Anti-tumour response to modified self-epitopesSCANCELL LTD·Filed 2018·Application pending·0 cites
- 0761US2008085278A1Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancerSCANCELL LTD·Filed 2007·Application pending·0 cites
- 0857US2006240003A1Humanised antibodies to the epidermal growth factor receptorSCANCELL LTD·Filed 2006·Application pending·0 cites
- 0952US11382985B2Anti-tumour immune responses to modified self-epitopesSCANCELL LTD·Filed 2020·Granted Jul 12, 2022·0 cites·14 claims
- 1051US12552876B2Anti-fucosyl-GM1 antibodiesSCANCELL LTD·Filed 2020·Granted Feb 17, 2026·0 cites·10 claims
- 1151US2023173047A1Citrullinated nucleophosmin peptides as cancer vaccinesSCANCELL LTD·Filed 2021·Application pending·0 cites
- 1250US2025269000A1Anti-tumour responses to cytokeratinsSCANCELL LTD·Filed 2021·Application pending·0 cites
- 1349US2022324997A1Ssea-4 binding membersSCANCELL LTD·Filed 2020·Application pending·0 cites
- 1448US2023310584A1Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigenSCANCELL LTD·Filed 2021·Application pending·0 cites
- 1546US12458688B2EpitopesSCANCELL LTD·Filed 2019·Granted Nov 4, 2025·0 cites·8 claims
- 1644US2022267465A1Binding membersSCANCELL LTD·Filed 2020·Application pending·0 cites
- 1743US12595313B2Modified Fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereofSCANCELL LTD·Filed 2020·Granted Apr 7, 2026·0 cites·15 claims
- 1830US6258528B1Signal amplification methodSCANCELL LTD·Filed 1999·Granted Jul 10, 2001·1 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when SCANCELL LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →